Clinical Trials

Overview

About this study

As CTS is the most commonly diagnosed compression neuropathy of the upper extremity, assessment of severity and treatment response is important crucial to determine the clinical outcomes. Currently, physical examination and overall functional status as well as pre-op electrodiagnostic (EDX) testing are important in determining patient outcome scores and assessing the treatment response. The physical properties of MN and surrounding tissue may be good biomarkers for this evaluation.

SWE is a qualitative and quantitative method for measuring tissue stiffness. There are limited studies on using SWE for diagnosis of CTS , but other aspects of CTS, including the assessment of severity and treatment response have not been studied. Our central hypothesis is that SWE provides quantitative information about the physical properties of the MN and surrounding tissue that help to identify carpal tunnel syndrome, its severity and response to treatment. If SWE successfully demonstrates efficacy in diagnosing, patient outcome score, and treatment response assessment, it would have a significant clinical impact on patients with CTS, as well as offering an additional confirmatory diagnostic test for true recurrent carpal tunnel syndrome.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Participating Mayo Clinic locations

More information